Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Oct;83(8):1069–1076. doi: 10.1054/bjoc.2000.1399

Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines

J R Kroep 1, G Giaccone 1, C Tolis 1, D A Voorn 1, W J P Loves 1, C J van Groeningen 1, H M Pinedo 1, G J Peters 1
PMCID: PMC2363564  PMID: 10993656

Abstract

Gemcitabine and paclitaxel are active agents in the treatment of non-small-cell lung cancer (NSCLC). To optimize treatment drug combinations, simultaneously and 4 and 24 h intervals, were studied using DNA flow cytometry and multiple drug effect analysis in the NSCLC cell lines H460, H322 and Lewis Lung. All combinations resulted in comparable cytotoxicity, varying from additivity to antagonism (combination index: 1.0–2.6). Gemcitabine caused a S (48%) and G1 (64%) arrest at IC-50 and 10 × IC-50 concentrations, respectively. Paclitaxel induced G2/M arrest (70%) which was maximal within 24 h at 10 × IC-50. Simultaneous treatment increased S-phase arrest, while at the 24 h interval after 72 h the first drug seemed to dominate the effect. Apoptosis was more pronounced when paclitaxel preceded gemcitabine (20% for both intervals) as compared to the reverse sequence (8%, P = 0.173 for the 4 h and 12%, P = 0.051 for the 24 h time interval). In H460 cells, paclitaxel increased 2-fold the accumulation of dFdCTP, the active metabolite of gemcitabine, in contrast to H322 cells. Paclitaxel did not affect deoxycytidine kinase levels, but ribonucleotide levels increased possibly explaining the increase in dFdCTP. Paclitaxel did not affect gemcitabine incorporation into DNA, but seemed to increase incorporation into RNA. Gemcitabine almost completely inhibited DNA synthesis in both cell lines (70–89%), while paclitaxel had a minor effect and did not increase that of gemcitabine. In conclusion, various gemcitabine–paclitaxel combinations did not show sequence dependent cytotoxic effects; all combinations were not more than additive. However, since paclitaxel increased dFdCTP accumulation, gemcitabine incorporation into RNA and the apoptotic index, the administration of paclitaxel prior to gemcitabine might be favourable as compared to reversed sequences. © 2000 Cancer Research Campaign

Keywords: gemcitabine, paclitaxel, NSCLC cell lines, cell cycle, cytotoxicity, dFdCTP

Full Text

The Full Text of this article is available as a PDF (117.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bouffard D. Y., Momparler R. L. Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res. 1995 Nov;19(11):849–856. doi: 10.1016/0145-2126(95)00067-4. [DOI] [PubMed] [Google Scholar]
  2. Chou T. C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4. [DOI] [PubMed] [Google Scholar]
  3. Dombernowsky P., Giaccone G., Sandler A., Schwartsmann G. Gemcitabine and paclitaxel combinations in non-small cell lung cancer. Semin Oncol. 1998 Aug;25(4 Suppl 9):44–50. [PubMed] [Google Scholar]
  4. Giaccone G., Smit E. F., van Meerbeeck J. P., Splinter T., Golding R. P., Pinedo H. M., Laan D., van Tinteren H., Postmus P. E. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. Ann Oncol. 2000 Jan;11(1):109–112. doi: 10.1023/a:1008321000887. [DOI] [PubMed] [Google Scholar]
  5. Hahn S. M., Liebmann J. E., Cook J., Fisher J., Goldspiel B., Venzon D., Mitchell J. B., Kaufman D. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer. 1993 Nov 1;72(9):2705–2711. doi: 10.1002/1097-0142(19931101)72:9<2705::aid-cncr2820720930>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  6. Heinemann V., Hertel L. W., Grindey G. B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988 Jul 15;48(14):4024–4031. [PubMed] [Google Scholar]
  7. Heinemann V., Schulz L., Issels R. D., Plunkett W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol. 1995 Aug;22(4 Suppl 11):11–18. [PubMed] [Google Scholar]
  8. Hertel L. W., Boder G. B., Kroin J. S., Rinzel S. M., Poore G. A., Todd G. C., Grindey G. B. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res. 1990 Jul 15;50(14):4417–4422. [PubMed] [Google Scholar]
  9. Huang P., Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol. 1995;36(3):181–188. doi: 10.1007/BF00685844. [DOI] [PubMed] [Google Scholar]
  10. Huang P., Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol. 1995;36(3):181–188. doi: 10.1007/BF00685844. [DOI] [PubMed] [Google Scholar]
  11. Jordan M. A., Toso R. J., Thrower D., Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9552–9556. doi: 10.1073/pnas.90.20.9552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jordan M. A., Wendell K., Gardiner S., Derry W. B., Copp H., Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996 Feb 15;56(4):816–825. [PubMed] [Google Scholar]
  13. Keepers Y. P., Pizao P. E., Peters G. J., van Ark-Otte J., Winograd B., Pinedo H. M. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer. 1991;27(7):897–900. doi: 10.1016/0277-5379(91)90142-z. [DOI] [PubMed] [Google Scholar]
  14. Kroep J. R., Giaccone G., Voorn D. A., Smit E. F., Beijnen J. H., Rosing H., van Moorsel C. J., van Groeningen C. J., Postmus P. E., Pinedo H. M. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol. 1999 Jul;17(7):2190–2197. doi: 10.1200/JCO.1999.17.7.2190. [DOI] [PubMed] [Google Scholar]
  15. Liebmann J. E., Fisher J., Teague D., Cook J. A. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res. 1994;6(1):25–31. [PubMed] [Google Scholar]
  16. Mayo J. G. Biologic characterization of the subcutaneously implanted Lewis lung tumor. Cancer Chemother Rep 2. 1972 Nov;3(1):325–330. [PubMed] [Google Scholar]
  17. Nicoletti I., Migliorati G., Pagliacci M. C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991 Jun 3;139(2):271–279. doi: 10.1016/0022-1759(91)90198-o. [DOI] [PubMed] [Google Scholar]
  18. Pritchard D. M., Watson A. J., Potten C. S., Jackman A. L., Hickman J. A. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1795–1799. doi: 10.1073/pnas.94.5.1795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rajkumar S. V., Adjei A. A. A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer. Cancer Treat Rev. 1998 Feb;24(1):35–53. doi: 10.1016/s0305-7372(98)90070-6. [DOI] [PubMed] [Google Scholar]
  20. Rothenberg M. L., Sharma A., Weiss G. R., Villalona-Calero M. A., Eckardt J. R., Aylesworth C., Kraynak M. A., Rinaldi D. A., Rodriguez G. I., Burris H. A., 3rd Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol. 1998 Jul;9(7):733–738. doi: 10.1023/a:1008286908930. [DOI] [PubMed] [Google Scholar]
  21. Rowinsky E. K., Citardi M. J., Noe D. A., Donehower R. C. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol. 1993;119(12):727–733. doi: 10.1007/BF01195344. [DOI] [PubMed] [Google Scholar]
  22. Rowinsky E. K., Donehower R. C., Jones R. J., Tucker R. W. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 1988 Jul 15;48(14):4093–4100. [PubMed] [Google Scholar]
  23. Rowinsky E. K., Donehower R. C. Paclitaxel (taxol) N Engl J Med. 1995 Apr 13;332(15):1004–1014. doi: 10.1056/NEJM199504133321507. [DOI] [PubMed] [Google Scholar]
  24. Ruiz van Haperen V. W., Veerman G., Boven E., Noordhuis P., Vermorken J. B., Peters G. J. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol. 1994 Oct 7;48(7):1327–1339. doi: 10.1016/0006-2952(94)90554-1. [DOI] [PubMed] [Google Scholar]
  25. Sasvári-Székely M., Spasokoukotskaja T., Szóke M., Csapó Z., Turi A., Szántó I., Eriksson S., Staub M. Activation of deoxycytidine kinase during inhibition of DNA synthesis by 2-chloro-2'-deoxyadenosine (Cladribine) in human lymphocytes. Biochem Pharmacol. 1998 Nov 1;56(9):1175–1179. doi: 10.1016/s0006-2952(98)00108-7. [DOI] [PubMed] [Google Scholar]
  26. Schiff P. B., Fant J., Horwitz S. B. Promotion of microtubule assembly in vitro by taxol. Nature. 1979 Feb 22;277(5698):665–667. doi: 10.1038/277665a0. [DOI] [PubMed] [Google Scholar]
  27. Seiter K., Feldman E. J., Traganos F., Li X., Halicka H. D., Darzynkiewicz Z., Lederman C. A., Romero M. B., Ahmed T. Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study of paclitaxel. Leukemia. 1995 Nov;9(11):1961–1966. [PubMed] [Google Scholar]
  28. Spasokoukotskaja T., Arnér E. S., Brosjö O., Gunvén P., Juliusson G., Liliemark J., Eriksson S. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer. 1995;31A(2):202–208. doi: 10.1016/0959-8049(94)00435-8. [DOI] [PubMed] [Google Scholar]
  29. Theodossiou C., Cook J. A., Fisher J., Teague D., Liebmann J. E., Russo A., Mitchell J. B. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol. 1998 Apr;12(4):825–832. doi: 10.3892/ijo.12.4.825. [DOI] [PubMed] [Google Scholar]
  30. Tolis C., Peters G. J., Ferreira C. G., Pinedo H. M., Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer. 1999 May;35(5):796–807. doi: 10.1016/s0959-8049(98)00425-0. [DOI] [PubMed] [Google Scholar]
  31. Torres K., Horwitz S. B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res. 1998 Aug 15;58(16):3620–3626. [PubMed] [Google Scholar]
  32. Winter S. F., Minna J. D., Johnson B. E., Takahashi T., Gazdar A. F., Carbone D. P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 1992 Aug 1;52(15):4168–4174. [PubMed] [Google Scholar]
  33. van Haperen V. W., Veerman G., Vermorken J. B., Pinedo H. M., Peters G. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine. Biochem Pharmacol. 1996 Apr 12;51(7):911–918. doi: 10.1016/0006-2952(95)02402-6. [DOI] [PubMed] [Google Scholar]
  34. van Moorsel CJ, Peters GJ, Pinedo HM. Gemcitabine: Future Prospects of Single-Agent and Combination Studies. Oncologist. 1997;2(3):127–134. [PubMed] [Google Scholar]
  35. van Moorsel C. J., Bergman A. M., Veerman G., Voorn D. A., Ruiz van Haperen V. W., Kroep J. R., Pinedo H. M., Peters G. J. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. Biochim Biophys Acta. 2000 Mar 6;1474(1):5–12. doi: 10.1016/s0304-4165(99)00209-3. [DOI] [PubMed] [Google Scholar]
  36. van Moorsel C. J., Pinedo H. M., Veerman G., Bergman A. M., Kuiper C. M., Vermorken J. B., van der Vijgh W. J., Peters G. J. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer. 1999 Jun;80(7):981–990. doi: 10.1038/sj.bjc.6690452. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES